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T
he old saying says, “When life gives you lemons, make lemonade” andwhen it comes to
laboratory experiments, researchers are typically given an awful lot of lemons. One of
the research areas that have suffered through more than its fair share of frustrating
experiments is human blood stem cell expansion where large numbers of failed
attempts to expand stem cells for their use in transplantation medicine have been recorded over the
decades. Mouse blood stem cell expansion on the other hand had a landmark paper1 last year
reporting >200-fold expansion of HSCs over a 1 month culture period. This has spurred a
renewed to begin to achieve the same sorts of numbers in human expansion cultures, making it a
very exciting area of science at present.
For immunological reasons, a preferred source of blood stem cells is cord blood, but cord blood
has some limitations when it comes to graft success, since the number of cells is finite.Whereas cord
blood transplantations are relatively routine in young children where the number of blood stem
cells per cord blood is often sufficient to achieve donor cell engraftment, this is not the case for all
adults where larger cell numbers are often in excess of what can be obtained from a single cord (one
of the field’s early pioneers, Hal Broxmeyer summarized the field quite nicely in this review2).
The mechanistic basis for this comes from the belief that the number of blood stem cells required
for a patient is in direct proportion to their weight, meaning that larger patients require much
higher doses of cord blood cells to obtain a sufficient number of stem cells. Dual cord blood
transplantations have been explored2 to see if simply adding inmore cells would be the answer, but
dual cord transplantations have their own complications as the blood cells fight to establish
themselves in the new environment (N.B. this is a fascinating process and not particularly well-
understood from a mechanistic point of view). Moreover, clinical evidence suggests3 that
alloreactivity can be increased by having two cord blood sources (as opposed to one) transplanted
into a recipient. So, in the absence of enough stem cells in a single cord, options to increase numbers
are limited, hence the incredible amount of research time and money invested in trying to expand
the stem cell number in cord bloods prior to transplantation.
Curiously, we do not often discuss what it means to have “increased blood stem cells” in a pot
of cells and as with nearly everything in the field of blood stem cells, the assays to demonstrate
functionality are retrospective and consequently highly reliant on the permissiveness of the
assay. It may, therefore, be just as important to ask the question of whether there are more
“potential stem cells” in a cord blood than the ones that read out in a transplantation setting. If
they were indeed found to be present, how might they be engaged to be productive in a
transplantation scenario? This is exactly what Gupta et al., investigated in their recent paper
entitled “Nov/CCN3 enhances cord blood engraftment by rapidly recruiting latent human stem
cell activity”4 which was an exciting read. The study began with the hypothesis that some
fraction of blood stem cells was present in a cord blood, but ineffective in transplantation
because they were not appropriately prepared to engraft in a host. They had done a fair amount
of previous work to identify the candidate NOV as a potential modulator of blood stem cells and
this paper really focused on testing its ability to improve the frequency of cells able to engraft
(rather than to expand them through self-renewal expansion divisions). Conceptually this is a
really neat idea and suggests that priming stem cells for transplantation may be worth investing
considerably more energy into.
Perhaps the most compelling experiment was a head-to-head comparison of CD34+ cells treated
for 8hours with NOV or not. Following rigorous limiting dilution primary and secondary
transplantation experiments in mice, it was clear that the NOV-treated cells were superior in their
ability to perform as functional stem cells in transplantation. Importantly, no cells divide in this
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short 8-hour culture, thereby excluding in vitro HSC expansion
as a mechanism. This latter point was supported by in vitro single
cell assays and the paper ends up concluding that coaxing cells to
be in the correct “state” for subsequent engraftment could be
achieved.
Previous studies have hinted that cell cycle regulation and
“quiescence exit” in particular would be critical to our ability to
manipulate how blood stem cells are called into action. CDK6
levels were identified by the Dick5 and Sexl groups6 in 2015 as a
key regulator of quiescence exit and understanding its molecular
mechanism would help determine the speed at which a blood
stem cell could leave its hibernating state. Other studies have
focused on the initial harvest of cord blood from donors. Of
interest here is the work of Mantel/O’Leary et al7 who showed
that reducing the loss of stem cells in a cord blood harvest
could be achieved by not exposing them to extra-physiological
oxygen levels.
Together, these multiple lines of evidence suggest that the
potential for large numbers of stem cells exist in a single cord and
it is down to the research community to identify the best method
of preserving and/or activating them to be most productive in a
post-transplantation scenario where they must seed the produc-
tion of blood cells for the remainder of the patient’s lifetime.
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